Expert OpinionOperational UpdatePharma/Biotech Clinical

Kymera Therapeutics To Announce Results From BroADen Phase 1b Clinical Trial Evaluating KT-621, Oral STAT6 Degrader, In Patients With Moderate To Severe AD On December 8

Benzinga•December 05, 2025 at 9:03 PM•Full Content

View Original →

📊 Workflow Status

✓ CompletedCompleted in 2s

clean_raw_article

✓ completed

→

clean_markdown_article

✓ completed

→

analyze_article

✓ completed

→

link_article_to_stories

⊘ skipped

→

analyze_sentiment

⊘ skipped

Workflow #3556 • Benzinga Article Processing

Started: 21:03:30 • Completed: 21:03:32

View Details →

Gist

Kymera Therapeutics will release Phase 1b trial results for KT-621, an oral STAT6 degrader, in moderate to severe atopic dermatitis patients on December 8, 2025.

LLM Summary

Kymera Therapeutics is set to announce results from its BroADen Phase 1b clinical trial of KT-621, an oral STAT6 degrader, in patients with moderate to severe atopic dermatitis. The results will be released via press release at 7:00 a.m. ET on December 8, 2025, followed by a webcast at 8:00 a.m. ET. The trial evaluates a novel oral small molecule degrader for immunological diseases.

Full Article Content

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the BroADen Phase 1b clinical trial evaluating KT-621, its oral STAT6 degrader, in patients with moderate to severe atopic dermatitis (AD) on Monday, December 8, 2025. A press release detailing the results will be issued at 7:00 a.m. ET, followed by a video conference call and webcast at 8:00 a.m. ET.

[Kymera Therapeutics, Inc.](https://www.globenewswire.com/Tracker?data=10kwJv6GEgpKW_neqvml9Q0KttCJMcJQiZ7Affna6mun_Ejj4SOl6A1bqVH4kMIzvzQvTRoOl0sys32NI7IrfvCJya7QwKOkRAMRtfYlAKc=) (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the BroADen Phase 1b clinical trial evaluating KT-621, its oral STAT6 degrader, in patients with moderate to severe atopic dermatitis (AD) on Monday, December 8, 2025. A press release detailing the results will be issued at 7:00 a.m. ET, followed by a video conference call and webcast at 8:00 a.m. ET.

<p><a href="https://www.globenewswire.com/Tracker?data=10kwJv6GEgpKW_neqvml9Q0KttCJMcJQiZ7Affna6mun_Ejj4SOl6A1bqVH4kMIzvzQvTRoOl0sys32NI7IrfvCJya7QwKOkRAMRtfYlAKc=">Kymera Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/KYMR">KYMR</a>), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the BroADen Phase 1b clinical trial evaluating KT-621, its oral STAT6 degrader, in patients with moderate to severe atopic dermatitis (AD) on Monday, December 8, 2025. A press release detailing the results will be issued at 7:00 a.m. ET, followed by a video conference call and webcast at 8:00 a.m. ET.</p>

Metadata

Author:

Benzinga Newsdesk

Tickers:

KYMR

Updated At:

December 05, 2025 at 5:03 PM

Benzinga Channels:

News

Teaser:

Benzinga Stocks:

KYMR (NASDAQ)

Benzinga Article ID:

49242075